- Home
- CTSO vs ATRA Comparison
CTSO vs ATRA Comparison
Compare CTSO & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- ATRA
- Stock Information
- Founded
- CTSO 1997
- ATRA 2012
- Country
- CTSO United States
- ATRA United States
- Employees
- CTSO N/A
- ATRA N/A
- Industry
- CTSO Medical/Dental Instruments
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTSO Health Care
- ATRA Health Care
- Exchange
- CTSO Nasdaq
- ATRA Nasdaq
- Market Cap
- CTSO 61.7M
- ATRA 67.9M
- IPO Year
- CTSO N/A
- ATRA 2014
- Fundamental
- Price
- CTSO $1.00
- ATRA $11.95
- Analyst Decision
- CTSO Buy
- ATRA Strong Buy
- Analyst Count
- CTSO 2
- ATRA 3
- Target Price
- CTSO $5.50
- ATRA $21.00
- AVG Volume (30 Days)
- CTSO 123.9K
- ATRA 60.0K
- Earning Date
- CTSO 11-06-2025
- ATRA 08-11-2025
- Dividend Yield
- CTSO N/A
- ATRA N/A
- EPS Growth
- CTSO N/A
- ATRA N/A
- EPS
- CTSO N/A
- ATRA 0.56
- Revenue
- CTSO $36,107,520.00
- ATRA $188,667,000.00
- Revenue This Year
- CTSO $11.93
- ATRA N/A
- Revenue Next Year
- CTSO $21.22
- ATRA N/A
- P/E Ratio
- CTSO N/A
- ATRA $21.25
- Revenue Growth
- CTSO 20.18
- ATRA 202.41
- 52 Week Low
- CTSO $0.71
- ATRA $5.01
- 52 Week High
- CTSO $1.61
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- CTSO 52.14
- ATRA 50.90
- Support Level
- CTSO $0.94
- ATRA $11.70
- Resistance Level
- CTSO $0.99
- ATRA $13.20
- Average True Range (ATR)
- CTSO 0.07
- ATRA 0.70
- MACD
- CTSO 0.01
- ATRA -0.07
- Stochastic Oscillator
- CTSO 82.21
- ATRA 35.14
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).